November 18, 2026
Health news, explained with evidence
LIVE

New Clinical Guidance Issued for First Immunotherapy Targeting Pediatric Type 1 Diabetes

❤️ Conditions & Care 2 min read 👁 10

Experts have published practical recommendations for using the immunotherapy drug teplizumab in children and adolescents newly diagnosed with stage 3 type 1 diabetes.

New Clinical Guidance Issued for First Immunotherapy Targeting Pediatric Type 1 Diabetes❤️Conditions & Care

Photo: Medical Xpress

Key points

  • New clinical guidance assists care teams in administering teplizumab for newly diagnosed pediatric type 1 diabetes.
  • The immunotherapy aims to preserve remaining insulin-producing beta cells, supplementing traditional insulin therapy.
  • Treatment requires administration within eight weeks of diagnosis and demands careful monitoring for immune-related side effects.

A national collaboration of pediatric diabetes specialists and clinical trial investigators has released new clinical guidance to help medical teams and families navigate an approved immunotherapy for young patients. Led by researchers at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz, the framework addresses how to evaluate candidates, discuss risks and benefits, and incorporate the treatment into standard care regimens.

The therapy, known as teplizumab, received expanded approval from the U.S. Food and Drug Administration (FDA) in June 2026 for children and adolescents aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes. While insulin remains necessary for managing blood sugar levels when symptoms first appear, teplizumab works by targeting the underlying autoimmune process, aiming to slow the immune system's destruction of remaining insulin-producing beta cells. The approval was granted via the accelerated pathway based on data from the PROTECT clinical trial.

In the PROTECT study involving 328 pediatric participants, those receiving the immunotherapy retained significantly more endogenous insulin production after 78 weeks compared to the placebo group. The treatment is administered through two separate 12-day courses of intravenous infusions spaced six months apart, and it must be initiated within eight weeks of a formal diagnosis. Potential side effects range from mild reactions like rash and headache to more serious risks, including temporary lymphocyte drops, infections, and cytokine release syndrome.

What to know: Teplizumab is not a cure and does not replace insulin therapy, but rather offers a way to preserve remaining beta-cell function during the early stages of type 1 diabetes. Patients and families should consult a qualified healthcare professional to determine if this specialized treatment is appropriate.

Source Medical Xpress — medicalxpress.com/news/2026-11-guidance-outlines-immunotherapy-children… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.